Biomarker results from a phase II randomized study of lapatinib (GW572016) as first-line treatment for patients with ErbB2 FISH-amplified advanced or metastatic breast cancer

被引：0
|
作者：
Gomez, HL
Chavez, MA
Doval, DC
Nag, S
Chow, LW
Ang, PC
Ahmad, NM
Berger, M
Newstat, B
Stein, S
Sledge, GW
机构：
[1] Inst Especializado Enfermedades Neoplas, Lima, Peru
[2] Hosp Alberto Sabogal, Lima, Peru
[3] Rajiv Gandhi Canc Inst & Res Ctr, New Delhi, India
[4] Jehangir Hosp & Med Ctr, Pune, Maharashtra, India
[5] Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China
[6] Natl Canc Ctr, Singapore, Singapore
[7] Univ Hosp, Bharu, Kalatan, Malaysia
[8] GlaxoSmithKline Inc, Collegeville, PA USA
[9] Indiana Univ, Indianapolis, IN 46204 USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S63 / S63
页数：1
相关论文
共 50 条
  • [1] Interim results of a phase II randomized study of lapatinib (GW572016) as first-line treatment for patients with FISH-amplified advanced or metastatic breast cancer
    Stein, S. H.
    Gomez, H. L.
    Chavez, M. A.
    Doval, D. C.
    Chow, L. W.
    Newstat, B.
    Berger, M. S.
    Sledge, G. W.
    EJC SUPPLEMENTS, 2005, 3 (02): : 78 - 78
  • [2] Updated biomarker results from a phase II randomized study of lapatinib as first-line treatment for patients with ErbB2-amplified advanced or metastatic breast cancer.
    Gomez, H. L.
    Chavez, M. A.
    Doval, D. C.
    Nag, S.
    Chow, L. W.
    Chang, P. C.
    Ahmad, N. M.
    Berger, M.
    Arbushites, M.
    Westlund, R.
    Stanislaus, M.
    Zaks, T.
    Stein, S.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S68 - S68
  • [3] Phase II clinical study of lapatinib (GW572016) in patients with advanced or metastatic breast cancer.
    Iwata, H.
    Toi, M.
    Fujiwara, Y.
    Ito, Y.
    Fujii, H.
    Nakamura, S.
    Aogi, K.
    Zaks, T.
    Sasaki, Y.
    Takashima, S.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S68 - S68
  • [4] Phase I study of lapatinib (GW572016) in combination with trastuzumab in advanced ErbB2-positive breast cancer
    Storniolo, A. M.
    Burris, H. A., III
    Pegram, M. D.
    Overmoyer, B.
    Miller, K.
    Jones, S. F.
    Silverman, P.
    Paul, E.
    Loftiss, J.
    Pandite, L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 78 - 78
  • [5] Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer
    Iqbal, S.
    Goldman, B.
    Fenoglio-Preiser, C. M.
    Lenz, H. J.
    Zhang, W.
    Danenberg, K. D.
    Shibata, S. I.
    Blanke, C. D.
    ANNALS OF ONCOLOGY, 2011, 22 (12) : 2610 - 2615
  • [6] S0413: A phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer
    Iqbal, S.
    Goldman, B.
    Lenz, H. J.
    Fenoglio-Preiser, C. M.
    Blanke, C. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Determining molecular phenotypes of metastatic breast cancer that respond to the small molecule inhibitor of ErbB1 and ErbB2, lapatinib (GW572016)
    Blackwell, KL
    Kaplan, EH
    Franco, SX
    Marcom, PK
    Maleski, JE
    Spector, NL
    Stocum, MT
    Sorensen, MJ
    Berger, MS
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S30 - S30
  • [8] Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer
    Gomez, Henry L.
    Doval, Dinesh C.
    Chavez, Miguel A.
    Ang, Peter C. -S.
    Aziz, Zeba
    Nag, Shona
    Ng, Christina
    Franco, Sandra X.
    Chow, Louis W. C.
    Arbushites, Michael C.
    Casey, Michelle A.
    Berger, Mark S.
    Stein, Steven H.
    Sledge, George W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (18) : 2999 - 3005
  • [9] Preliminary safety results of a phase II trial comparing two schedules of lapatinib (GW572016) as first line therapy for advanced or metastatic non-small cell lung cancer.
    Ross, HJ
    Blumenschein, GR
    Dowlati, A
    Aisner, J
    Rigas, JR
    Stanislaus, M
    Leopold, LH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 645S - 645S
  • [10] A phase II, open-label, multicenter study of lapatinib (GW572016) in patients with metastatic breast cancer that has progressed on trastuzumab-containing reimens
    Blackwell, Kimberly
    Kaplan, Edward H.
    Franco, Sandra X.
    Marcom, P. Kelly
    Maleski, Janet
    Sorensen, Mel
    Berger, Mark S.
    ANNALS OF ONCOLOGY, 2004, 15 : 27 - 27
12345